Loading
PDBj
MenuPDBj@FacebookPDBj@TwitterPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

4QV0

yCP beta5-A49T-A50V-double mutant

Summary for 4QV0
Entry DOI10.2210/pdb4qv0/pdb
Related1RYP 4QTR 4QUX 4QV0 4QV1 4QV3 4QV4 4QV5 4QV6 4QV7 4QV8 4QV9 4QVL 4QVM 4QVN 4QVP 4QVQ
DescriptorProteasome subunit alpha type-2, Proteasome subunit beta type-4, Proteasome subunit beta type-5, ... (17 entities in total)
Functional Keywordscancer, proteasome, bortezomib, drug resistance, binding analysis, hydrolase
Biological sourceSaccharomyces cerevisiae (Baker's yeast)
More
Total number of polymer chains28
Total formula weight731383.67
Authors
Huber, E.M.,Heinemeyer, W.,Groll, M. (deposition date: 2014-07-14, release date: 2015-02-04, Last modification date: 2023-09-20)
Primary citationHuber, E.M.,Heinemeyer, W.,Groll, M.
Bortezomib-Resistant Mutant Proteasomes: Structural and Biochemical Evaluation with Carfilzomib and ONX 0914.
Structure, 23:407-417, 2015
Cited by
PubMed Abstract: Inhibition of the 20S proteasome by bortezomib (Velcade) constitutes a successfully applied therapy for blood cancer. However, emerging resistance restricts its medicinal use. For example, mutations in the proteolytically active β5-subunit of the proteasome, the main target of inhibitors, were reported to impair drug binding and thus to reduce therapeutic efficacy. Using yeast as a model system, we describe here a systematic evaluation of these mutations by cell growth analysis, proteasome inhibition assays, and X-ray crystallography. The 11 mutants examined display decreased proliferation rates, impaired proteolytic activity, and marked resistance to bortezomib as well as the α',β'-epoxyketone inhibitors carfilzomib (Kyprolis) and ONX 0914, while the second-generation compound carfilzomib was the least affected. In total, 49 proteasome X-ray structures, including structural data on proteasome-carfilzomib complexes, reveal three distinct molecular mechanisms that hamper both drug binding and natural substrate turnover to an extent that is still compatible with cell survival.
PubMed: 25599643
DOI: 10.1016/j.str.2014.11.019
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (3.1 Å)
Structure validation

227111

數據於2024-11-06公開中

PDB statisticsPDBj update infoContact PDBjnumon